Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138084 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction (DDI) Rifabutin
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
NCT02138084 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 102 participants.
The verdict
NCT02138084, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to provide dosing recommendations for the coadministration of BMS-663068 and Rifabutin with and without Ritonavir in upcoming Phase 3 studies and for prescribing information purposes
Interventions
- DRUG Ritonavir
- DRUG Rifabutin
- DRUG BMS-663068
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2014-05-14 |
| Est. Completion | 2014-07-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02138084
The ClinicalTrials.gov registry entry for NCT02138084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ritonavir is the first listed.
NCT02138084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02138084 about?
NCT02138084 is a clinical study titled "Drug-drug Interaction (DDI) Rifabutin". The purpose of this study is to provide dosing recommendations for the coadministration of BMS-663068 and Rifabutin with and without Ritonavir in upcoming Phase 3 studies and for prescribing information purposes
What is the current status of trial NCT02138084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2014-05-14. Estimated completion is 2014-07-24.
What interventions are being tested in trial NCT02138084?
The interventions under investigation include: Ritonavir (DRUG), Rifabutin (DRUG), BMS-663068 (DRUG).
Who is sponsoring clinical trial NCT02138084?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.